Xarelto: first novel anticoagulant licensed for ACS

Bayer has launched a new 2.5mg strength of Xarelto (rivaroxaban) for the prevention of atherothrombotic events after acute coronary syndromes (ACS) in patients with elevated cardiac biomarkers.

Rivaroxaban is a selective direct factor Xa inhibitor. | SCIENCE PHOTO LIBRARY
Rivaroxaban is a selective direct factor Xa inhibitor. | SCIENCE PHOTO LIBRARY

In ACS patients, rivaroxaban is administered at a dose of 2.5mg twice daily in combination with aspirin 75—100mg daily, with or without clopidogrel 75mg daily.1

Efficacy

The safety and efficacy of rivaroxaban was evaluated in 15,526 patients with a recent ACS, defined as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina.1

When added to standard therapy including low-dose aspirin, rivaroxaban 2.5mg twice daily significantly reduced the primary composite endpoint of death from cardiovascular causes, MI or stroke compared with placebo, with rates of 9.1% and 10.7%, respectively, over 24 months (HR 0.84, 95% CI 0.72—0.97, p=0.02).2

Rivaroxaban also significantly reduced the risk of death from cardiovascular causes (2.7%, vs 4.1% for placebo, p=0.002) and death from any cause (2.9%, vs 4.5% for placebo, p=0.002) over 24 months.2

Safety

Rivaroxaban increased the risk of major bleeding not associated with coronary-artery bypass grafting (1.8%, vs 0.6% with placebo; HR 3.46, 95% CI 2.08—5.77, p<0.001), as well as the rate of bleeding requiring medical attention and the rate of intracranial haemorrhage. However, there was no statistically significant difference in fatal bleeding.2

NICE decision pending

A technology appraisal assessing the clinical and cost effectiveness of rivaroxaban for secondary prevention in ACS is due to be published in March 2015.

References:

  1. Xarelto Summary of Product Characteristics, July 2014.

View Xarelto drug record

Further information: Bayer plc

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Drug shortages - live tracker

Drug shortages - live tracker

Added: fludroxycortide, levofloxacin, Noriday, Ongentys...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...

Thiazides better than ACE inhibitors as first-line antihypertensives, large-scale analysis suggests